A

Arizona Neuroscience Research, LLC | Phoenix, AZ

Research site

(Unclaimed)

Location

3805 E Bell Rd, Suite 2400, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

ABP-450

Ocrelizumab

Ofatumumab

PIPE-307

Cladribine

Cenobamate

MTR-601

Bafiertam

ABP-19000

Simufilam

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 15 total trials

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (SOSTOS)

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab ve...

Active, not recruiting

Relapsing-Remitting Multiple Sclerosis

Drug: Disease modifying treatment (DMT)

Drug: Ofatumumab

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myas...

Enrolling

Generalized Myasthenia Gravis

Drug: Cladribine Low Dose

Drug: Cladribine High Dose

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of...

Active, not recruiting

Focal Onset Seizure

Drug: Cenobamate

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of...

Active, not recruiting

Relapse Remitting Multiple Sclerosis

Drug: Ofatumumab